Lv7
3450 积分 2022-12-19 加入
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy
2天前
求助中
Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma
20天前
已完结
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
20天前
已完结
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment
29天前
已完结
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis
29天前
已完结
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
1个月前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
1个月前
已完结
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment
1个月前
已关闭
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma
1个月前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
1个月前
已完结
皖公网安备34019202002308
